Key Decision

  • The Administrative Committee of the Board of Directors of Piramal Pharma Limited, acting under authority delegated by the Board, approved the exercise of the Company's call option to acquire the balance 26% equity stake in Yapan Bio Private Limited from its existing shareholders.
  • The company is engaged in discussions with Yapan Bio's shareholders regarding matters necessary for consummation of the proposed transaction.

Current and Projected Ownership

  • Current shareholding: Piramal Pharma holds 74% equity stake in Yapan Bio Private Limited
  • Post-transaction shareholding: Expected to increase to 100%, making Yapan Bio a wholly-owned subsidiary

Transaction Status

  • Final terms including acquisition consideration and effective date of share transfer are yet to be finalized
  • Appropriate disclosures will be made upon execution of definitive documentation and completion of the transaction as required under Regulation 30 of SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025CFD-POD2/I/3762/2026 dated January 30, 2026

Business Description of Target Company

Yapan Bio Private Limited is a Contract Development and Manufacturing Organization (CDMO) that specializes in:

  • Process development
  • Characterization
  • Phase I/II GMP manufacturing services for vaccines and biologics